The influence of age on the management of anal cancer

The standard treatment for anal cancer is combination chemo-radiotherapy. Management decisions such as radical chemotherapy, resective surgery for poor response or relapse are frequently modified by age-associated comorbid factors. Between 1980 and 1990, our regional cancer center serving a population of 1.8 million saw 78 patients with squamous carcinoma of the anus. We have compared patients who were younger than 65 years (n=38) with those older than 65 years (n=38). The mean ± standard deviation age for the whole cohort was 65±12 years, with a ratio of 2 females to each male presenting. Fewer of the elderly age group had major surgery (26% vs. 42%) (p=0.03), and fewer suffered no toxicity (42% vs. 26%) (p=0.03). However, 61% of the under-65-year age group are alive disease-free vs. 26% of the elderly group (p=0.03). Similarly, only 18% of the under-65-year group died with disease compared with 37% of the elderly group (b=0.03). For the series as a whole, the crude mortality was 42%, with 27% dying of their disease. The stage distribution, and the amount of radiotherapy or chemotherapy administered was not age-specific, but younger patients had more surgery and suffered more toxicity, with a greater proportion remaining alive and disease-free, and fewer dying of their disease. These data suggest that a more aggressive multi-modality approach in the elderly may improve disease response and survival